| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Abnormalities, Drug-Induced | 33 | 2023 | 317 | 6.940 |
Why?
|
| Pregnancy Complications | 42 | 2022 | 2861 | 4.070 |
Why?
|
| Anticonvulsants | 21 | 2023 | 1916 | 2.890 |
Why?
|
| Pregnancy Outcome | 23 | 2022 | 2795 | 2.610 |
Why?
|
| Prenatal Exposure Delayed Effects | 29 | 2022 | 2408 | 2.480 |
Why?
|
| Pregnancy | 156 | 2023 | 29144 | 2.460 |
Why?
|
| Pregnancy Complications, Infectious | 13 | 2022 | 2026 | 2.250 |
Why?
|
| Pregnancy Trimester, First | 31 | 2023 | 853 | 2.010 |
Why?
|
| Cleft Palate | 10 | 2020 | 560 | 1.540 |
Why?
|
| Abortion, Spontaneous | 7 | 2023 | 544 | 1.470 |
Why?
|
| Peptic Ulcer | 6 | 2011 | 223 | 1.430 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 17 | 2012 | 2282 | 1.420 |
Why?
|
| Persistent Fetal Circulation Syndrome | 4 | 2015 | 80 | 1.370 |
Why?
|
| Congenital Abnormalities | 12 | 2020 | 707 | 1.350 |
Why?
|
| Maternal Age | 8 | 2023 | 802 | 1.330 |
Why?
|
| Birth Order | 2 | 2019 | 95 | 1.300 |
Why?
|
| Fructose | 4 | 2014 | 288 | 1.260 |
Why?
|
| Medicaid | 23 | 2023 | 2736 | 1.220 |
Why?
|
| Antidepressive Agents | 9 | 2020 | 2838 | 1.190 |
Why?
|
| Drug Prescriptions | 12 | 2021 | 1637 | 1.080 |
Why?
|
| Registries | 22 | 2023 | 8089 | 1.050 |
Why?
|
| Perinatal Care | 5 | 2021 | 227 | 1.010 |
Why?
|
| Delivery, Obstetric | 5 | 2020 | 906 | 1.000 |
Why?
|
| Pregnancy, Multiple | 4 | 2018 | 217 | 0.980 |
Why?
|
| Infant, Newborn | 60 | 2023 | 25625 | 0.930 |
Why?
|
| Hydroxychloroquine | 4 | 2022 | 412 | 0.900 |
Why?
|
| Cohort Studies | 66 | 2023 | 40561 | 0.890 |
Why?
|
| Pre-Eclampsia | 10 | 2022 | 1200 | 0.890 |
Why?
|
| Paternal Exposure | 2 | 2020 | 89 | 0.850 |
Why?
|
| Cleft Lip | 7 | 2020 | 478 | 0.840 |
Why?
|
| Female | 194 | 2023 | 380194 | 0.830 |
Why?
|
| Gastrointestinal Hemorrhage | 9 | 2012 | 1130 | 0.820 |
Why?
|
| Stomach Ulcer | 4 | 2013 | 125 | 0.820 |
Why?
|
| Premature Birth | 10 | 2022 | 1721 | 0.810 |
Why?
|
| Heart Defects, Congenital | 16 | 2023 | 4584 | 0.800 |
Why?
|
| Infant, Small for Gestational Age | 5 | 2022 | 440 | 0.760 |
Why?
|
| Pregnancy Complications, Cardiovascular | 5 | 2018 | 500 | 0.760 |
Why?
|
| Epilepsy | 11 | 2023 | 3310 | 0.760 |
Why?
|
| Hypertension, Pregnancy-Induced | 6 | 2016 | 489 | 0.750 |
Why?
|
| Infant Mortality | 4 | 2019 | 754 | 0.740 |
Why?
|
| Teratogens | 2 | 2014 | 112 | 0.740 |
Why?
|
| Infertility | 3 | 2023 | 655 | 0.720 |
Why?
|
| Analgesics, Opioid | 15 | 2022 | 3674 | 0.710 |
Why?
|
| Maternal Exposure | 8 | 2019 | 961 | 0.700 |
Why?
|
| Peptic Ulcer Perforation | 3 | 2013 | 24 | 0.700 |
Why?
|
| Epidemiologic Methods | 5 | 2011 | 1364 | 0.670 |
Why?
|
| Risk | 26 | 2021 | 9687 | 0.670 |
Why?
|
| Selection Bias | 4 | 2020 | 371 | 0.670 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2019 | 144 | 0.660 |
Why?
|
| Adult | 117 | 2023 | 214055 | 0.660 |
Why?
|
| Humans | 219 | 2023 | 744343 | 0.640 |
Why?
|
| Fathers | 2 | 2020 | 358 | 0.640 |
Why?
|
| Antipsychotic Agents | 7 | 2023 | 3057 | 0.630 |
Why?
|
| Duodenal Ulcer | 2 | 2013 | 125 | 0.620 |
Why?
|
| Drug Utilization | 6 | 2019 | 1183 | 0.620 |
Why?
|
| Acetaminophen | 5 | 2020 | 545 | 0.610 |
Why?
|
| Folic Acid | 9 | 2016 | 1300 | 0.590 |
Why?
|
| Triazines | 3 | 2017 | 315 | 0.580 |
Why?
|
| Propensity Score | 14 | 2020 | 1781 | 0.570 |
Why?
|
| Anti-Retroviral Agents | 3 | 2015 | 1715 | 0.560 |
Why?
|
| Zidovudine | 2 | 2018 | 620 | 0.550 |
Why?
|
| Maternal Welfare | 2 | 2014 | 115 | 0.540 |
Why?
|
| Infant, Low Birth Weight | 3 | 2018 | 850 | 0.540 |
Why?
|
| Tryptamines | 2 | 2020 | 88 | 0.540 |
Why?
|
| United States | 64 | 2023 | 69872 | 0.540 |
Why?
|
| Antirheumatic Agents | 4 | 2021 | 1339 | 0.530 |
Why?
|
| Stillbirth | 5 | 2023 | 346 | 0.530 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2015 | 1873 | 0.530 |
Why?
|
| Lithium Compounds | 1 | 2017 | 225 | 0.530 |
Why?
|
| Postpartum Hemorrhage | 5 | 2020 | 258 | 0.530 |
Why?
|
| Prescription Drugs | 6 | 2023 | 595 | 0.520 |
Why?
|
| Reproductive Techniques, Assisted | 2 | 2023 | 482 | 0.510 |
Why?
|
| Case-Control Studies | 37 | 2021 | 21746 | 0.500 |
Why?
|
| Nonprescription Drugs | 5 | 2018 | 116 | 0.500 |
Why?
|
| Incidental Findings | 1 | 2019 | 689 | 0.490 |
Why?
|
| Risk Factors | 59 | 2022 | 72290 | 0.490 |
Why?
|
| Hypoglycemic Agents | 3 | 2019 | 2872 | 0.490 |
Why?
|
| Young Adult | 50 | 2023 | 56430 | 0.480 |
Why?
|
| Lithium | 1 | 2017 | 601 | 0.480 |
Why?
|
| Antihypertensive Agents | 9 | 2020 | 2046 | 0.480 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2002 | 365 | 0.480 |
Why?
|
| HIV Infections | 13 | 2021 | 16718 | 0.470 |
Why?
|
| Proton Pump Inhibitors | 4 | 2013 | 526 | 0.470 |
Why?
|
| Intention to Treat Analysis | 2 | 2013 | 426 | 0.470 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2010 | 1203 | 0.450 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2013 | 49 | 0.440 |
Why?
|
| Neural Tube Defects | 5 | 2013 | 256 | 0.440 |
Why?
|
| Prevalence | 22 | 2023 | 15226 | 0.440 |
Why?
|
| Brain Ischemia | 3 | 2022 | 3265 | 0.440 |
Why?
|
| Folic Acid Antagonists | 3 | 2003 | 84 | 0.440 |
Why?
|
| Opioid-Related Disorders | 7 | 2022 | 2065 | 0.440 |
Why?
|
| Metformin | 2 | 2018 | 835 | 0.430 |
Why?
|
| Neonatal Abstinence Syndrome | 3 | 2022 | 109 | 0.430 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2010 | 162 | 0.430 |
Why?
|
| Aspirin | 5 | 2011 | 3282 | 0.410 |
Why?
|
| Fetal Death | 1 | 2014 | 448 | 0.410 |
Why?
|
| Anti-HIV Agents | 5 | 2021 | 4256 | 0.400 |
Why?
|
| Tetracyclines | 1 | 2011 | 60 | 0.400 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2012 | 141 | 0.400 |
Why?
|
| Gastrointestinal Diseases | 4 | 2006 | 1170 | 0.400 |
Why?
|
| Immune System Diseases | 1 | 2014 | 262 | 0.390 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2019 | 1240 | 0.390 |
Why?
|
| Sweden | 8 | 2021 | 1345 | 0.380 |
Why?
|
| Amines | 1 | 2012 | 276 | 0.380 |
Why?
|
| Logistic Models | 18 | 2021 | 13408 | 0.370 |
Why?
|
| Migraine Disorders | 2 | 2020 | 1620 | 0.360 |
Why?
|
| Databases, Factual | 12 | 2022 | 7729 | 0.350 |
Why?
|
| Pediatrics | 2 | 2015 | 3475 | 0.350 |
Why?
|
| Language Development | 3 | 2016 | 187 | 0.350 |
Why?
|
| Congresses as Topic | 1 | 2014 | 764 | 0.350 |
Why?
|
| Placenta Diseases | 2 | 2022 | 199 | 0.350 |
Why?
|
| Risk Assessment | 23 | 2020 | 23338 | 0.350 |
Why?
|
| Incidence | 22 | 2021 | 20947 | 0.340 |
Why?
|
| Antiviral Agents | 1 | 2021 | 2987 | 0.340 |
Why?
|
| Pregnant Women | 5 | 2021 | 568 | 0.320 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2010 | 275 | 0.320 |
Why?
|
| Antiemetics | 2 | 2020 | 177 | 0.320 |
Why?
|
| Spinal Dysraphism | 2 | 2020 | 161 | 0.310 |
Why?
|
| Mood Disorders | 2 | 2017 | 1106 | 0.310 |
Why?
|
| Algorithms | 10 | 2022 | 13881 | 0.310 |
Why?
|
| Infant | 19 | 2023 | 35136 | 0.310 |
Why?
|
| Phthalic Acids | 2 | 2011 | 436 | 0.310 |
Why?
|
| Fetal Growth Retardation | 2 | 2022 | 570 | 0.310 |
Why?
|
| Abruptio Placentae | 2 | 2022 | 118 | 0.300 |
Why?
|
| Fertility Agents | 1 | 2007 | 11 | 0.300 |
Why?
|
| Middle Aged | 52 | 2022 | 213383 | 0.300 |
Why?
|
| Hypertension | 8 | 2018 | 8480 | 0.300 |
Why?
|
| Pharmacoepidemiology | 4 | 2013 | 323 | 0.300 |
Why?
|
| Norway | 7 | 2020 | 448 | 0.300 |
Why?
|
| Asthma | 4 | 2021 | 6011 | 0.290 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 1320 | 0.280 |
Why?
|
| Adolescent | 33 | 2022 | 85781 | 0.280 |
Why?
|
| Drug Therapy, Combination | 8 | 2018 | 6489 | 0.280 |
Why?
|
| Comparative Effectiveness Research | 1 | 2011 | 681 | 0.280 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2012 | 1121 | 0.270 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2009 | 1205 | 0.270 |
Why?
|
| Cerebral Palsy | 1 | 2010 | 459 | 0.270 |
Why?
|
| Stroke | 4 | 2022 | 9981 | 0.270 |
Why?
|
| Tetanus Toxoid | 1 | 2006 | 193 | 0.270 |
Why?
|
| Birth Weight | 3 | 2019 | 2069 | 0.270 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 4149 | 0.270 |
Why?
|
| Diclofenac | 1 | 2006 | 71 | 0.270 |
Why?
|
| Gestational Age | 9 | 2023 | 3493 | 0.270 |
Why?
|
| Labor, Induced | 2 | 2017 | 146 | 0.270 |
Why?
|
| Odds Ratio | 11 | 2021 | 9849 | 0.260 |
Why?
|
| Interviews as Topic | 2 | 2011 | 2539 | 0.260 |
Why?
|
| Models, Statistical | 5 | 2019 | 5102 | 0.250 |
Why?
|
| Drug Utilization Review | 2 | 2018 | 245 | 0.250 |
Why?
|
| Medication Adherence | 3 | 2011 | 2063 | 0.250 |
Why?
|
| Diabetes, Gestational | 3 | 2019 | 1184 | 0.240 |
Why?
|
| Benzodiazepines | 2 | 2022 | 1101 | 0.240 |
Why?
|
| Ondansetron | 3 | 2020 | 90 | 0.240 |
Why?
|
| Pregnancy Trimester, Third | 4 | 2015 | 571 | 0.240 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2005 | 284 | 0.240 |
Why?
|
| Mental Disorders | 3 | 2021 | 6600 | 0.230 |
Why?
|
| Pharmaceutical Preparations | 3 | 2011 | 1071 | 0.230 |
Why?
|
| Gastroschisis | 2 | 2023 | 97 | 0.230 |
Why?
|
| Research Design | 4 | 2021 | 5987 | 0.230 |
Why?
|
| Smoking | 9 | 2015 | 8987 | 0.230 |
Why?
|
| Lactones | 1 | 2006 | 329 | 0.230 |
Why?
|
| Sulfones | 1 | 2006 | 437 | 0.230 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 535 | 0.230 |
Why?
|
| Rheumatic Diseases | 2 | 2012 | 592 | 0.220 |
Why?
|
| Hypospadias | 2 | 2011 | 92 | 0.220 |
Why?
|
| Fetal Development | 3 | 2016 | 767 | 0.220 |
Why?
|
| Male | 58 | 2023 | 350118 | 0.220 |
Why?
|
| Anti-Infective Agents | 3 | 2014 | 972 | 0.210 |
Why?
|
| Anxiety | 7 | 2021 | 4297 | 0.210 |
Why?
|
| Fetal Diseases | 2 | 2020 | 903 | 0.210 |
Why?
|
| Hydroxyprogesterones | 1 | 2021 | 25 | 0.210 |
Why?
|
| Psychomotor Disorders | 1 | 2003 | 152 | 0.210 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2002 | 54 | 0.210 |
Why?
|
| Diethylstilbestrol | 1 | 2002 | 93 | 0.210 |
Why?
|
| Myocardial Infarction | 6 | 2018 | 11727 | 0.200 |
Why?
|
| Aged | 33 | 2022 | 163280 | 0.200 |
Why?
|
| Epilepsy, Generalized | 1 | 2023 | 174 | 0.200 |
Why?
|
| Live Birth | 2 | 2022 | 512 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 3255 | 0.200 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2017 | 1518 | 0.200 |
Why?
|
| Postpartum Period | 5 | 2021 | 1086 | 0.200 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2014 | 456 | 0.200 |
Why?
|
| Confidence Intervals | 4 | 2011 | 2971 | 0.190 |
Why?
|
| Canada | 5 | 2018 | 2065 | 0.190 |
Why?
|
| Calcium Channel Blockers | 2 | 2015 | 690 | 0.190 |
Why?
|
| North America | 2 | 2023 | 1249 | 0.190 |
Why?
|
| Valproic Acid | 1 | 2023 | 445 | 0.190 |
Why?
|
| Postmenopause | 1 | 2010 | 2461 | 0.190 |
Why?
|
| Epidemiologic Research Design | 1 | 2004 | 367 | 0.190 |
Why?
|
| Anencephaly | 1 | 2020 | 20 | 0.190 |
Why?
|
| Mothers | 4 | 2021 | 2165 | 0.190 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2020 | 25 | 0.190 |
Why?
|
| Causality | 4 | 2010 | 1275 | 0.180 |
Why?
|
| Lung Neoplasms | 4 | 2010 | 13102 | 0.180 |
Why?
|
| Prescriptions | 5 | 2023 | 387 | 0.180 |
Why?
|
| Fluconazole | 1 | 2020 | 146 | 0.180 |
Why?
|
| Intestinal Perforation | 1 | 2002 | 253 | 0.180 |
Why?
|
| Bipolar Disorder | 1 | 2017 | 5027 | 0.180 |
Why?
|
| Environmental Exposure | 3 | 2011 | 4234 | 0.180 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2019 | 1855 | 0.180 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2021 | 3658 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2022 | 10943 | 0.170 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 4328 | 0.170 |
Why?
|
| Coronary Disease | 2 | 2013 | 6077 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 4 | 2011 | 7181 | 0.170 |
Why?
|
| Birth Intervals | 1 | 2018 | 51 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2014 | 3309 | 0.160 |
Why?
|
| Nausea | 3 | 2023 | 673 | 0.160 |
Why?
|
| Child | 18 | 2023 | 77709 | 0.160 |
Why?
|
| Siblings | 3 | 2017 | 854 | 0.160 |
Why?
|
| Lactation | 1 | 2021 | 412 | 0.160 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2021 | 615 | 0.160 |
Why?
|
| Polypharmacy | 1 | 2020 | 294 | 0.160 |
Why?
|
| Safety | 2 | 2014 | 1186 | 0.160 |
Why?
|
| Contraceptives, Oral | 2 | 2010 | 564 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2011 | 1790 | 0.150 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2016 | 2559 | 0.150 |
Why?
|
| Amphetamine | 1 | 2018 | 225 | 0.140 |
Why?
|
| Vaccination | 2 | 2023 | 3278 | 0.140 |
Why?
|
| Gastrointestinal Agents | 1 | 2021 | 494 | 0.140 |
Why?
|
| AIDS-Related Complex | 1 | 2016 | 110 | 0.140 |
Why?
|
| Pregnancy in Diabetics | 1 | 2018 | 179 | 0.140 |
Why?
|
| Body Size | 1 | 2019 | 461 | 0.140 |
Why?
|
| Haloperidol | 1 | 2018 | 397 | 0.140 |
Why?
|
| Spain | 3 | 2008 | 465 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 3923 | 0.140 |
Why?
|
| Patient Compliance | 2 | 2020 | 2684 | 0.140 |
Why?
|
| Reproduction | 1 | 2001 | 668 | 0.140 |
Why?
|
| Inappropriate Prescribing | 1 | 2018 | 202 | 0.140 |
Why?
|
| Puerperal Disorders | 1 | 2018 | 275 | 0.130 |
Why?
|
| Lipid A | 1 | 2015 | 67 | 0.130 |
Why?
|
| Aluminum Hydroxide | 1 | 2015 | 58 | 0.130 |
Why?
|
| Colorado | 1 | 2015 | 163 | 0.130 |
Why?
|
| Antifungal Agents | 1 | 2020 | 730 | 0.130 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 12354 | 0.130 |
Why?
|
| Cesarean Section | 2 | 2018 | 1365 | 0.130 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2015 | 30 | 0.130 |
Why?
|
| Fractures, Bone | 1 | 2007 | 1947 | 0.130 |
Why?
|
| Time Factors | 10 | 2022 | 40075 | 0.130 |
Why?
|
| Comorbidity | 4 | 2020 | 10388 | 0.130 |
Why?
|
| Pregnancy Trimesters | 2 | 2014 | 192 | 0.130 |
Why?
|
| Vomiting | 2 | 2023 | 636 | 0.130 |
Why?
|
| Clinical Coding | 1 | 2016 | 171 | 0.120 |
Why?
|
| Child, Preschool | 12 | 2023 | 41006 | 0.120 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2016 | 156 | 0.120 |
Why?
|
| Bradycardia | 1 | 2016 | 307 | 0.120 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2019 | 536 | 0.120 |
Why?
|
| Education | 2 | 2015 | 543 | 0.120 |
Why?
|
| Viral Load | 2 | 2016 | 3299 | 0.120 |
Why?
|
| Vitamin B Complex | 1 | 2016 | 288 | 0.120 |
Why?
|
| Body Height | 2 | 1999 | 1577 | 0.120 |
Why?
|
| Methylergonovine | 1 | 2013 | 6 | 0.120 |
Why?
|
| District of Columbia | 1 | 2014 | 157 | 0.120 |
Why?
|
| Placenta, Retained | 1 | 2013 | 21 | 0.120 |
Why?
|
| Methylphenidate | 1 | 2018 | 473 | 0.120 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 430 | 0.120 |
Why?
|
| Depressive Disorder | 4 | 2015 | 3748 | 0.120 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2014 | 140 | 0.120 |
Why?
|
| Population Surveillance | 2 | 2020 | 2616 | 0.110 |
Why?
|
| Antimanic Agents | 1 | 2017 | 522 | 0.110 |
Why?
|
| Epidemiology | 1 | 2016 | 287 | 0.110 |
Why?
|
| Retrospective Studies | 15 | 2021 | 77449 | 0.110 |
Why?
|
| Arthritis, Psoriatic | 1 | 2016 | 215 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2009 | 4558 | 0.110 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 57776 | 0.110 |
Why?
|
| Oxytocics | 1 | 2013 | 68 | 0.110 |
Why?
|
| Insurance, Health | 4 | 2023 | 2494 | 0.110 |
Why?
|
| Methadone | 1 | 2015 | 306 | 0.110 |
Why?
|
| Latent Tuberculosis | 1 | 2015 | 225 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2015 | 7913 | 0.110 |
Why?
|
| Nervous System | 1 | 2016 | 554 | 0.110 |
Why?
|
| Fetus | 3 | 2020 | 1880 | 0.110 |
Why?
|
| Insurance Benefits | 1 | 2014 | 183 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2001 | 1253 | 0.110 |
Why?
|
| Language Development Disorders | 1 | 2014 | 196 | 0.110 |
Why?
|
| Child Behavior Disorders | 1 | 2017 | 807 | 0.110 |
Why?
|
| Anti-Anxiety Agents | 1 | 2014 | 390 | 0.100 |
Why?
|
| HIV-1 | 1 | 2010 | 6939 | 0.100 |
Why?
|
| Kidney Diseases | 2 | 2016 | 2149 | 0.100 |
Why?
|
| Prospective Studies | 10 | 2018 | 53288 | 0.100 |
Why?
|
| Excipients | 1 | 2011 | 96 | 0.100 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2019 | 1695 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2006 | 3079 | 0.100 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 15540 | 0.100 |
Why?
|
| New York | 1 | 2014 | 886 | 0.100 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 720 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 5751 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2000 | 2107 | 0.100 |
Why?
|
| Sex Factors | 4 | 2013 | 10397 | 0.100 |
Why?
|
| Mental Recall | 2 | 2011 | 1205 | 0.100 |
Why?
|
| Child Development | 1 | 2003 | 2223 | 0.100 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 159 | 0.100 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12261 | 0.100 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2016 | 582 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6538 | 0.090 |
Why?
|
| Morphine | 1 | 2015 | 657 | 0.090 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2016 | 3712 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 17446 | 0.090 |
Why?
|
| Dietary Supplements | 4 | 2011 | 3297 | 0.090 |
Why?
|
| Carbamazepine | 1 | 2011 | 229 | 0.090 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2012 | 320 | 0.090 |
Why?
|
| Europe | 3 | 2016 | 3339 | 0.090 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 39050 | 0.090 |
Why?
|
| Cross-Over Studies | 5 | 2010 | 2029 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 2 | 2010 | 2716 | 0.090 |
Why?
|
| Denmark | 2 | 2023 | 738 | 0.090 |
Why?
|
| Histamine H2 Antagonists | 1 | 2011 | 165 | 0.090 |
Why?
|
| Pregnancy, Unplanned | 1 | 2010 | 95 | 0.090 |
Why?
|
| Age Factors | 5 | 2013 | 18370 | 0.090 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2013 | 306 | 0.090 |
Why?
|
| Pain | 4 | 2020 | 4986 | 0.090 |
Why?
|
| Pandemics | 4 | 2022 | 8388 | 0.090 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 867 | 0.090 |
Why?
|
| Self Report | 2 | 2018 | 3558 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 19905 | 0.090 |
Why?
|
| Central Nervous System | 1 | 2017 | 1357 | 0.090 |
Why?
|
| Embryonic Development | 1 | 2014 | 711 | 0.080 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 1912 | 0.080 |
Why?
|
| Hypoglycemia | 1 | 2016 | 861 | 0.080 |
Why?
|
| Papillomavirus Vaccines | 1 | 2015 | 491 | 0.080 |
Why?
|
| Heart Failure | 3 | 2013 | 10900 | 0.080 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 2690 | 0.080 |
Why?
|
| Didanosine | 1 | 2008 | 153 | 0.080 |
Why?
|
| Theophylline | 1 | 2008 | 132 | 0.080 |
Why?
|
| Crohn Disease | 1 | 2021 | 2303 | 0.080 |
Why?
|
| Retinopathy of Prematurity | 1 | 2013 | 421 | 0.080 |
Why?
|
| Pain, Postoperative | 1 | 2018 | 1643 | 0.080 |
Why?
|
| Bioterrorism | 1 | 2009 | 143 | 0.080 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2013 | 469 | 0.080 |
Why?
|
| Omeprazole | 1 | 2008 | 112 | 0.080 |
Why?
|
| Mesalamine | 1 | 2008 | 136 | 0.080 |
Why?
|
| Synaptic Transmission | 1 | 2014 | 1178 | 0.080 |
Why?
|
| Seizures | 2 | 2022 | 2859 | 0.080 |
Why?
|
| RNA, Viral | 1 | 2016 | 2902 | 0.080 |
Why?
|
| Insurance Claim Reporting | 1 | 2008 | 163 | 0.080 |
Why?
|
| Ibuprofen | 2 | 2006 | 236 | 0.080 |
Why?
|
| Antitubercular Agents | 1 | 2015 | 1320 | 0.080 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2015 | 912 | 0.080 |
Why?
|
| Birth Certificates | 2 | 2022 | 67 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 3022 | 0.070 |
Why?
|
| Infant, Premature, Diseases | 1 | 2013 | 706 | 0.070 |
Why?
|
| Ventilators, Mechanical | 1 | 2009 | 292 | 0.070 |
Why?
|
| Biological Products | 1 | 2016 | 860 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 4933 | 0.070 |
Why?
|
| Morning Sickness | 1 | 2006 | 5 | 0.070 |
Why?
|
| Mental Health | 1 | 2021 | 3019 | 0.070 |
Why?
|
| Recurrence | 3 | 2021 | 8340 | 0.070 |
Why?
|
| Community Pharmacy Services | 1 | 2007 | 46 | 0.070 |
Why?
|
| Endotoxins | 1 | 2009 | 527 | 0.070 |
Why?
|
| Fertilization | 1 | 2008 | 196 | 0.070 |
Why?
|
| Tennessee | 3 | 2014 | 117 | 0.070 |
Why?
|
| Databases as Topic | 2 | 2011 | 475 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2016 | 1580 | 0.070 |
Why?
|
| Hypnotics and Sedatives | 1 | 2014 | 1162 | 0.070 |
Why?
|
| Depression | 5 | 2021 | 7766 | 0.070 |
Why?
|
| Age Distribution | 2 | 2023 | 2902 | 0.070 |
Why?
|
| Helicobacter pylori | 1 | 2009 | 382 | 0.070 |
Why?
|
| Helicobacter Infections | 1 | 2009 | 386 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2010 | 12026 | 0.070 |
Why?
|
| Parity | 1 | 2009 | 929 | 0.070 |
Why?
|
| Food Supply | 1 | 2011 | 524 | 0.070 |
Why?
|
| Naproxen | 1 | 2006 | 99 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 14722 | 0.070 |
Why?
|
| Overweight | 2 | 2023 | 2371 | 0.070 |
Why?
|
| Labetalol | 2 | 2016 | 30 | 0.070 |
Why?
|
| Food, Fortified | 1 | 2006 | 191 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2011 | 899 | 0.060 |
Why?
|
| Monte Carlo Method | 1 | 2010 | 1254 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2017 | 2133 | 0.060 |
Why?
|
| Ontario | 2 | 2005 | 383 | 0.060 |
Why?
|
| International Cooperation | 1 | 2011 | 1420 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2011 | 6459 | 0.060 |
Why?
|
| Pharmacists | 1 | 2007 | 248 | 0.060 |
Why?
|
| Medicare | 2 | 2020 | 6566 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 1432 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2018 | 5317 | 0.060 |
Why?
|
| Research | 2 | 2021 | 1999 | 0.060 |
Why?
|
| Physical Exertion | 1 | 2007 | 695 | 0.060 |
Why?
|
| Reference Values | 1 | 2011 | 4982 | 0.060 |
Why?
|
| Demography | 1 | 2009 | 1656 | 0.060 |
Why?
|
| Environment | 1 | 2010 | 1124 | 0.060 |
Why?
|
| Preconception Care | 1 | 2005 | 134 | 0.060 |
Why?
|
| Infant, Premature | 1 | 2013 | 2044 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 2104 | 0.060 |
Why?
|
| Chlorprothixene | 1 | 2023 | 3 | 0.060 |
Why?
|
| Trachea | 1 | 2009 | 1076 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 11124 | 0.060 |
Why?
|
| Mediterranean Sea | 1 | 2002 | 12 | 0.060 |
Why?
|
| Psychotic Disorders | 1 | 2018 | 3046 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2017 | 9146 | 0.060 |
Why?
|
| Estrogens | 1 | 2010 | 1566 | 0.060 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 2624 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 1 | 2010 | 1504 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2015 | 1912 | 0.050 |
Why?
|
| Urinary Tract | 2 | 2010 | 309 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2009 | 15076 | 0.050 |
Why?
|
| Placenta | 2 | 2022 | 1698 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 20822 | 0.050 |
Why?
|
| Learning | 1 | 2012 | 1713 | 0.050 |
Why?
|
| Disease Progression | 1 | 2019 | 13284 | 0.050 |
Why?
|
| Research Subjects | 1 | 2004 | 239 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2014 | 3743 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4468 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2020 | 3913 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 2569 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 3508 | 0.050 |
Why?
|
| Aminosalicylic Acid | 1 | 2021 | 21 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 1681 | 0.050 |
Why?
|
| Data Collection | 2 | 2008 | 3341 | 0.050 |
Why?
|
| Steroids | 2 | 2011 | 930 | 0.050 |
Why?
|
| Caffeine | 1 | 2006 | 699 | 0.050 |
Why?
|
| Coffee | 1 | 2006 | 578 | 0.050 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 1537 | 0.050 |
Why?
|
| Sulfasalazine | 1 | 2021 | 79 | 0.050 |
Why?
|
| Semen | 1 | 2023 | 316 | 0.050 |
Why?
|
| Mexico | 2 | 2002 | 690 | 0.050 |
Why?
|
| Health Status | 2 | 2009 | 4034 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2011 | 2158 | 0.050 |
Why?
|
| Neoplasms | 1 | 2010 | 21683 | 0.050 |
Why?
|
| Anticoagulants | 2 | 2013 | 4599 | 0.050 |
Why?
|
| New South Wales | 1 | 2020 | 66 | 0.050 |
Why?
|
| Half-Life | 1 | 2001 | 661 | 0.050 |
Why?
|
| Family | 2 | 2023 | 3147 | 0.050 |
Why?
|
| Peru | 2 | 2014 | 881 | 0.050 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 25043 | 0.050 |
Why?
|
| Hong Kong | 1 | 2020 | 148 | 0.050 |
Why?
|
| Acute Disease | 3 | 2013 | 7149 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2015 | 63114 | 0.040 |
Why?
|
| Italy | 2 | 2012 | 832 | 0.040 |
Why?
|
| Acute Coronary Syndrome | 1 | 2013 | 2337 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2010 | 3494 | 0.040 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2020 | 95 | 0.040 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 329 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 6895 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 240 | 0.040 |
Why?
|
| Loneliness | 1 | 2021 | 185 | 0.040 |
Why?
|
| Socioeconomic Factors | 5 | 2010 | 7785 | 0.040 |
Why?
|
| Finland | 1 | 2020 | 602 | 0.040 |
Why?
|
| Disease | 1 | 2004 | 680 | 0.040 |
Why?
|
| DiGeorge Syndrome | 1 | 2020 | 177 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2005 | 3588 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2023 | 1959 | 0.040 |
Why?
|
| Down Syndrome | 1 | 2006 | 880 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2007 | 880 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 11725 | 0.040 |
Why?
|
| Intention | 1 | 2021 | 341 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2011 | 3068 | 0.040 |
Why?
|
| Nutrition Disorders | 1 | 1999 | 211 | 0.040 |
Why?
|
| Urban Population | 2 | 2011 | 2021 | 0.040 |
Why?
|
| Family Practice | 1 | 2001 | 516 | 0.040 |
Why?
|
| Germany | 1 | 2020 | 862 | 0.040 |
Why?
|
| Central Nervous System Stimulants | 1 | 2006 | 1148 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 1420 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2009 | 2958 | 0.040 |
Why?
|
| Parturition | 1 | 2021 | 441 | 0.040 |
Why?
|
| Rural Health | 1 | 1999 | 305 | 0.040 |
Why?
|
| Netherlands | 2 | 2012 | 2170 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2007 | 2057 | 0.040 |
Why?
|
| Drug and Narcotic Control | 1 | 2018 | 146 | 0.040 |
Why?
|
| Psychotropic Drugs | 1 | 2003 | 894 | 0.040 |
Why?
|
| Lamivudine | 1 | 2018 | 342 | 0.040 |
Why?
|
| Epidemiologic Studies | 1 | 2000 | 676 | 0.040 |
Why?
|
| Costa Rica | 2 | 2007 | 177 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 1170 | 0.040 |
Why?
|
| Outpatients | 2 | 2016 | 1486 | 0.040 |
Why?
|
| Atenolol | 1 | 2016 | 100 | 0.030 |
Why?
|
| Ritonavir | 1 | 2018 | 322 | 0.030 |
Why?
|
| Metoprolol | 1 | 2016 | 93 | 0.030 |
Why?
|
| Stress, Psychological | 2 | 2021 | 4245 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 13989 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2002 | 1660 | 0.030 |
Why?
|
| Risperidone | 1 | 2018 | 383 | 0.030 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2002 | 810 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2000 | 1726 | 0.030 |
Why?
|
| Arthritis | 1 | 2000 | 659 | 0.030 |
Why?
|
| Internationality | 1 | 2021 | 1003 | 0.030 |
Why?
|
| Insulin | 1 | 2010 | 6580 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 1683 | 0.030 |
Why?
|
| Cognition | 1 | 2012 | 6770 | 0.030 |
Why?
|
| Health Surveys | 2 | 2021 | 4037 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2021 | 1530 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2021 | 1184 | 0.030 |
Why?
|
| Codeine | 1 | 2014 | 49 | 0.030 |
Why?
|
| Hydrocodone | 1 | 2014 | 47 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2019 | 6196 | 0.030 |
Why?
|
| Alleles | 1 | 2005 | 6933 | 0.030 |
Why?
|
| Methyldopa | 1 | 2013 | 20 | 0.030 |
Why?
|
| Uterine Inertia | 1 | 2013 | 29 | 0.030 |
Why?
|
| Developed Countries | 1 | 2016 | 437 | 0.030 |
Why?
|
| Obstetric Labor, Premature | 1 | 2014 | 279 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2009 | 8554 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2013 | 188 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2013 | 475 | 0.030 |
Why?
|
| Prenatal Care | 1 | 2020 | 1092 | 0.030 |
Why?
|
| HIV | 1 | 2020 | 1604 | 0.030 |
Why?
|
| Prognosis | 2 | 2019 | 29063 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 2020 | 1236 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2021 | 1338 | 0.030 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 547 | 0.030 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2012 | 48 | 0.030 |
Why?
|
| Rural Population | 2 | 1999 | 2210 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2004 | 3589 | 0.030 |
Why?
|
| Vitamins | 1 | 2000 | 1622 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2019 | 1359 | 0.030 |
Why?
|
| Educational Status | 1 | 1999 | 2540 | 0.030 |
Why?
|
| Government Regulation | 1 | 2016 | 522 | 0.020 |
Why?
|
| Women's Health | 1 | 2021 | 2034 | 0.020 |
Why?
|
| Opiate Substitution Treatment | 1 | 2015 | 404 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2009 | 4644 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 419 | 0.020 |
Why?
|
| Thiazoles | 1 | 2018 | 1483 | 0.020 |
Why?
|
| Genotype | 1 | 2005 | 12951 | 0.020 |
Why?
|
| Anti-Ulcer Agents | 1 | 2011 | 119 | 0.020 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 688 | 0.020 |
Why?
|
| Disease Management | 1 | 2021 | 2459 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2011 | 513 | 0.020 |
Why?
|
| Nitrates | 1 | 2011 | 265 | 0.020 |
Why?
|
| State Medicine | 1 | 2011 | 217 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2007 | 12720 | 0.020 |
Why?
|
| Sepsis | 2 | 2013 | 2593 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 3798 | 0.020 |
Why?
|
| Animals | 4 | 2014 | 168757 | 0.020 |
Why?
|
| Erythromycin | 1 | 2009 | 120 | 0.020 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2010 | 346 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2015 | 1534 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2015 | 2373 | 0.020 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2011 | 336 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 5391 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2011 | 968 | 0.020 |
Why?
|
| Amoxicillin | 1 | 2009 | 170 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2023 | 13033 | 0.020 |
Why?
|
| Piperazines | 1 | 2018 | 2488 | 0.020 |
Why?
|
| Azithromycin | 1 | 2009 | 196 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2018 | 2708 | 0.020 |
Why?
|
| Doxycycline | 1 | 2009 | 326 | 0.020 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2009 | 362 | 0.020 |
Why?
|
| Bronchodilator Agents | 1 | 2010 | 502 | 0.020 |
Why?
|
| Hospitalization | 2 | 2020 | 10262 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 2009 | 315 | 0.020 |
Why?
|
| Gravidity | 1 | 2006 | 51 | 0.020 |
Why?
|
| Linear Models | 1 | 2017 | 5952 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2010 | 651 | 0.020 |
Why?
|
| Hernia, Umbilical | 1 | 2007 | 96 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 2297 | 0.020 |
Why?
|
| Vaccines | 1 | 2014 | 822 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2009 | 565 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 1863 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2010 | 1460 | 0.020 |
Why?
|
| Ephedrine | 1 | 2005 | 54 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2016 | 1591 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2018 | 3313 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2019 | 6256 | 0.020 |
Why?
|
| Massachusetts | 2 | 2010 | 8663 | 0.020 |
Why?
|
| Twins | 1 | 2006 | 339 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3508 | 0.020 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2010 | 574 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 2618 | 0.020 |
Why?
|
| Philadelphia | 1 | 2005 | 266 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2009 | 1124 | 0.020 |
Why?
|
| Inpatients | 1 | 2016 | 2518 | 0.020 |
Why?
|
| Nervous System Malformations | 1 | 2006 | 247 | 0.020 |
Why?
|
| Counseling | 1 | 2011 | 1523 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2006 | 732 | 0.010 |
Why?
|
| Craniosynostoses | 1 | 2007 | 401 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 1416 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2009 | 1836 | 0.010 |
Why?
|
| Maternal Behavior | 1 | 2004 | 311 | 0.010 |
Why?
|
| Social Support | 1 | 2011 | 2118 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 2002 | 331 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2009 | 1167 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2011 | 2266 | 0.010 |
Why?
|
| Sputum | 1 | 2002 | 476 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2016 | 4258 | 0.010 |
Why?
|
| Maternal Health Services | 1 | 2005 | 455 | 0.010 |
Why?
|
| El Salvador | 1 | 1999 | 39 | 0.010 |
Why?
|
| Community Health Centers | 1 | 2002 | 430 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2000 | 611 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 7279 | 0.010 |
Why?
|
| Life Style | 1 | 2006 | 3835 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2005 | 2278 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2006 | 3188 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2007 | 3843 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 12245 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2000 | 7880 | 0.000 |
Why?
|